On Friday, Rapport Therapeutics Inc (NASDAQ: RAPP) opened higher 4.94% from the last session, before settling in for the closing price of $16.8. Price fluctuations for RAPP have ranged from $6.43 to $29.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 17.50% at the time writing. With a float of $17.46 million, this company’s outstanding shares have now reached $36.50 million.
Rapport Therapeutics Inc (RAPP) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Rapport Therapeutics Inc is 52.15%, while institutional ownership is 59.77%. The most recent insider transaction that took place on Aug 15 ’25, was worth 127,466. In this transaction Chief Scientific Officer of this company sold 8,500 shares at a rate of $15.00, taking the stock ownership to the 426,642 shares. Before that another transaction happened on Jul 15 ’25, when Company’s Chief Scientific Officer sold 8,500 for $14.00, making the entire transaction worth $118,962. This insider now owns 435,142 shares in total.
Rapport Therapeutics Inc (RAPP) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.5 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.52) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year. According to the Wall Street analysts, stocks earnings will be around 17.50% per share during the next fiscal year.
Rapport Therapeutics Inc (NASDAQ: RAPP) Trading Performance Indicators
Check out the current performance indicators for Rapport Therapeutics Inc (RAPP). In the past quarter, the stock posted a quick ratio of 22.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -4.14 in one year’s time.
Technical Analysis of Rapport Therapeutics Inc (RAPP)
Analysing the last 5-days average volume posted by the [Rapport Therapeutics Inc, RAPP], we can find that recorded value of 0.31 million was better than the volume posted last year of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 70.07%.
During the past 100 days, Rapport Therapeutics Inc’s (RAPP) raw stochastic average was set at 96.49%, which indicates a significant increase from 91.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.28 in the past 14 days, which was higher than the 1.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.25, while its 200-day Moving Average is $13.97. Now, the first resistance to watch is $18.38. This is followed by the second major resistance level at $19.14. The third major resistance level sits at $20.28. If the price goes on to break the first support level at $16.48, it is likely to go to the next support level at $15.34. Should the price break the second support level, the third support level stands at $14.58.
Rapport Therapeutics Inc (NASDAQ: RAPP) Key Stats
There are currently 36,498K shares outstanding in the company with a market cap of 643.46 million. Presently, the company’s annual sales total 0 K according to its annual income of -78,310 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -26,730 K.
